The use of virologically compromised organs in liver transplantation

Clinics in Liver Disease

Volumn 7, Issue 3, 2003, Pages 573-584

  Rodriguez Luna, Hector ^a   Arenas, Juan ^a   Vargas, Hugo E ^a  

^a MAYO CLINIC HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; LAMIVUDINE;

CHEMOPROPHYLAXIS; GENOTYPE; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; IMMUNOPROPHYLAXIS; LIVER DISEASE; LIVER GRAFT; LIVER TRANSPLANTATION; ORGAN DONOR; REVIEW; SURVIVAL; TREATMENT OUTCOME; VIRUS TRANSMISSION;

EID: 0042334665     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(03)00056-4     Document Type: Review

References (50)

1. UNOS and HHS/HRSA/OSP/DOT. 2000 Annual Report of the US Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network: Transplant Data 1991-2000. Available at: ustransplants.org, http://www.ustransplant.org/annual_reports/ar02/ar01_data Accessed 9/10/02.
2. Otero J, Rodriguez M, Escudero D, et al. Kidney transplants with positive anti-hepatitis C virus donors. Transplantation 1990;50:1086-7.
3. Pereira B, Milford E, Kirkman R, et al. Transmission of hepatitis C virus by organ transplantation. N Engl J Med 1991;325:454-60.
4. Pereira B, Milford E, Kirkman R, et al. Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med 1992;327: 910-5.
5. Wreghitt TG, Gray JJ, Allain JP, et al. Transmission of hepatitis C virus by organ transplantation in the United Kingdom. J Hepatol 1994;20:768-72.
6. Pereira BJ, Wright TL, Schmid CH, et al. A controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group. Lancet 1995;345: 484-7.
7. Pereira BJ, Wright TL, Schmid CH, et al. Screening and confirmatory testing of cadaver organ donors for hepatitis C virus infection: a US National Collaborative Study. Kidney Int 1994; 46:886-92.
8. Di Bisceglie AM. Liver transplantation for hepatitis C: the promise and the challenge [editorial comment]. Hepatology 1995;22:660-2.
9. Aswad S, Mendez R, Weingart RG. Expanding organ availability by using hepatitis C antibody positive donors. Transplant Proc 1993;25:2270-1.
10. Mulligan DC, Goldstein RM, Crippin JS, et al. Use of anti-hepatitis C virus seropositive organs in liver transplantation. Transplant Proc 1995;27:1204-5.
11. Feray C, Shouval D, Samuel D. Will transplantation of an hepatitis C-infected graft improve the outcome of liver transplantation in HCV patients? Gastroenterology 1999;117:263-5.
12. Testa G, Goldstein RM, Netto G, et al. Long-term outcome of patients transplanted with livers from hepatitis C-positive donors. Transplantation 1998;65:925-9.
13. Torres M, Weppler D, Reddy KR, et al. Use of hepatitis C-infected donors for hepatitis C-positive OLT recipients. Gastroenterology 1999;117:1253.
14. Vargas HE, Laskus T, Wang LF, et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology 1999; 117:149-53.
15. Velidedeoglu E, Desai NM, Campos L, et al. The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation 2002;73:582-7.
16. Ghobrial RM, Steadman R, Gombein J, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001; 234:384-93; discussion 393.
17. Marroquin CE, Marino G, Kuo PC, et al. Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver Transpl 2001;7:762-8.
18. Laskus T, Wang LF, Rakela J, et al. Dynamic behavior of hepatitis C virus in chronically infected patients receiving liver graft from infected donors. Virology 1996;220:171-6.
19. Radkowski M, Wang LF, Vargas H, et al. Changes in hepatitis C virus population in serum and peripheral blood mononuclear cells in chronically infected patients receiving liver graft from infected donors. Transplantation 2001;72:833-8.
20. Chazouilleres O, Mamish D, Kim M, et al. "Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994;343:142-6.
21. Todo S, Demetris AJ, Van Thiel D, et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991;13:619-26.
22. Benner KG, Lee RG, Keeffe EB, et al. Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation. Gastroenterology 1992;103:1307-12.
23. Corman JL, Putnam CW, Iwatsuki S, et al. Liver allograft. Its use in chronic active hepatitis with macronodular cirrhosis, hepatitis B surface antigen. Arch Surg 1979;114:75-8.
24. Davies SE, Portmann BC, O'Grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991;13:150-7.
25. Demetris AJ, Jaffe R, Sheahan DG, et al. Recurrent hepatitis B in liver allograft recipients. Differentiation between viral hepatitis B and rejection. Am J Pathol 1986;125:161-72.
26. Demetris AJ, Todo S, Van Thiel DH, et al. Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations. Am J Pathol 1990;137:667-76.
27. O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992;14:104-11.
28. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-7.
29. Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996;24:1327-33.
30. Anselmo DM, Ghobrial RM, Jung LC, et al. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 2002;235:611-9; discussion 619-20.
31. Wachs ME, Amend WJ, Ascher NL, et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995;59:230-4.
32. Roche B, Samuel D, Gigou M, et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 1997;26:517-26.
33. Fabia R, Levy MF, Crippin J, et al. De novo hepatitis B infection after liver transplantation: source of disease, incidence, and impact. Liver Transpl Surg 1998;4:119-27.
34. Dodson SF, Issa S, Araya V, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997;64:1582-4.
35. Prieto M, Gomez MD, Berenguer M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001;7:51-8.
36. Turner DP, Zuckerman M, Alexander GJ, et al. Risk of inappropriate exclusion of organ donors by introduction of hepatitis B core antibody testing. Transplantation 1997;63:775-7.
37. Dickson RC, Everhart JE, Lake JR, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997; 113:1668-74.
38. Aldersley MA, Eglin RE, O'Grady JG. Liver transplantation and de novo hepatitis B infection. Lancet 1994;343:677.
39. Dodson SF, Bonham CA, Geller DA, et al. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999;68: 1058-61.
40. Douglas DD, Rakela J, Wright TL, et al. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997;3:105-11.
41. Van Thiel DH, De Maria N, Colantoni A, et al. Can hepatitis B core antibody positive livers be used safely for transplantation: hepatitis B virus detection in the liver of individuals who are hepatitis B core antibody positive. Transplantation 1999;68:519-22.
42. Uemoto S, Sugiyama K, Marusawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998;65:494-9.
43. Manzarbeitia C, Reich DJ, Ortiz JA, et al. Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl 2002;8:556-61.
44. Dodson SF, de Vera ME, Bonham CA, et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000; 6:434-9.
45. Holt D, Thomas R, Van Thiel D, et al. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 2002;137:572-5.
46. Joya-Vazquez PP, Dodson FS, Dvorchik I, et al. Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis. Transplantation 2002;73:1598-602.
47. Castells L, Esteban R. Hepatitis B vaccination in liver transplant candidates. Eur J Gastroenterol Hepatol 2001;13:359-61.
48. Chalasani N, Smallwood G, Halcomb J, et al. Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation? Liver Transpl Surg 1998;4:128-32.
49. Dominguez M, Barcena R, Garcia M, et al. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl 2000;6:440-2.
50. Chung RT, Feng S, Delmonico FL. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transplant 2001; 1:185-91.